122497-48-7

Basic information

• Product Name: 9-ethyl-9H-carbazole-3-carbaldehyde oxime
• Synonyms: 9-ethyl-9H-carbazole-3-carbaldehyde oxime
• CAS NO: 122497-48-7
• Molecular Formula: C₁₅H₁₄N₂O
• Molecular Weight: 238.28446
• Mol File: 122497-48-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 9-ethyl-9H-carbazole-3-carbaldehyde oxime(CAS DataBase Reference)
• NIST Chemistry Reference: 9-ethyl-9H-carbazole-3-carbaldehyde oxime(122497-48-7)
• EPA Substance Registry System: 9-ethyl-9H-carbazole-3-carbaldehyde oxime(122497-48-7)

Safety Data

• Hazardous Substances Data: 122497-48-7(Hazardous Substances Data)

Upstream product

• 86-28-2 N-ethylcarbazole 
• 86-74-8 9H-carbazole 
• 7570-45-8 N-ethyl-3-carbazolealdehyde 

Relevant articles and documents

Morphology change from nanotube to vesicle and monolayer/bilayer alteration by amphiphilic block polypeptides having aromatic groups at c terminal

Various amphiphilic block polypeptides having aromatic groups at the C terminal of a Leu-based hydrophobic helical block, poly(sarcosine)-b-(L-Leu-Aib)6-ethylcarbazole, poly- (sarcosine)-b-(D-Leu-Aib)6-naphthalimide, and poly(sarcosine)- b-(D-Leu-Aib)6-po

HEPATITIS C VIRUS ENTRY INHIBITORS

The present invention relates to the use of tricyclic diphenylamine derivative compounds for prevention and/or treatment of Hepatitis C virus (HCV) infection by inhibiting HCV entry into permissive cells.

Carbazole lipoxygenase inhibiting compounds, compositions and use

Compounds of the formula: STR1 wherein R1 is hydrogen, C1 to C4 alkyl, C2 to C4 alkenyl, or NR2R3, wherein R2 and R3 are independently selected from hydrogen, C1 to C4 alkyl and hydroxyl, but R2 and R3 are not simultaneously hydroxyl; X is oxygen, sulfur, CO2, or NR4, wherein R4 is hydrogen, C1 to C6 alkyl, C1 to C6 alkoyl or aroyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; Y is selected independently at each occurrence from hydrogen, halogen, hydroxy, cyano, nitro, halosubstituted alkyl, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C3 to C8 cycloalkyl, aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, C1 to C12 arylthicalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, or C1 to C12 arylthioalkoxy, wherein C12 alkyl, alkoxy, and halosubstituted alkyl; n is a number having the values 0-4; when n=0 then Y=hydrogen; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl. These compounds are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.